Q3 Earnings Estimate for Bio-Techne Issued By KeyCorp

Bio-Techne Co. (NASDAQ:TECH) – KeyCorp issued their Q3 2025 earnings per share (EPS) estimates for shares of Bio-Techne in a report released on Tuesday, April 8th. KeyCorp analyst P. Knight anticipates that the biotechnology company will post earnings of $0.44 per share for the quarter. KeyCorp has a “Sector Weight” rating on the stock. The consensus estimate for Bio-Techne’s current full-year earnings is $1.67 per share. KeyCorp also issued estimates for Bio-Techne’s Q4 2025 earnings at $0.43 EPS.

Several other equities analysts also recently weighed in on TECH. Evercore ISI started coverage on Bio-Techne in a research report on Tuesday, March 18th. They set an “outperform” rating and a $75.00 target price on the stock. StockNews.com raised Bio-Techne from a “hold” rating to a “buy” rating in a research report on Friday, April 4th. Robert W. Baird lowered Bio-Techne from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $88.00 to $68.00 in a research note on Wednesday, February 19th. Citigroup dropped their price objective on Bio-Techne from $80.00 to $70.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Finally, Royal Bank of Canada boosted their target price on shares of Bio-Techne from $79.00 to $80.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 6th. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $81.25.

Bio-Techne Stock Performance

Shares of TECH stock opened at $50.72 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.77 and a current ratio of 3.94. Bio-Techne has a 1 year low of $46.44 and a 1 year high of $85.57. The firm has a market cap of $8.02 billion, a price-to-earnings ratio of 51.23, a PEG ratio of 2.88 and a beta of 1.45. The stock’s 50-day moving average is $61.32 and its two-hundred day moving average is $69.59.

Bio-Techne (NASDAQ:TECH) last announced its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%.

Institutional Trading of Bio-Techne

Several large investors have recently bought and sold shares of TECH. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Bio-Techne by 46.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,650 shares of the biotechnology company’s stock valued at $1,215,000 after acquiring an additional 5,295 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Bio-Techne by 58.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 43,298 shares of the biotechnology company’s stock valued at $3,119,000 after acquiring an additional 16,038 shares during the last quarter. Oddo BHF Asset Management Sas purchased a new position in shares of Bio-Techne in the third quarter valued at approximately $1,188,000. Fort Washington Investment Advisors Inc. OH boosted its stake in Bio-Techne by 11.2% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 254,034 shares of the biotechnology company’s stock worth $18,298,000 after purchasing an additional 25,650 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Bio-Techne by 12.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 736,340 shares of the biotechnology company’s stock valued at $52,641,000 after acquiring an additional 79,629 shares during the last quarter. Hedge funds and other institutional investors own 98.95% of the company’s stock.

Insider Activity at Bio-Techne

In other news, CEO Kim Kelderman sold 13,392 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the transaction, the chief executive officer now owns 39,004 shares of the company’s stock, valued at approximately $3,014,619.16. The trade was a 25.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Amy E. Herr sold 1,860 shares of Bio-Techne stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $65.96, for a total transaction of $122,685.60. Following the transaction, the director now directly owns 1,976 shares of the company’s stock, valued at approximately $130,336.96. This represents a 48.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.90% of the stock is owned by insiders.

Bio-Techne Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, February 28th. Shareholders of record on Monday, February 17th were paid a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a yield of 0.63%. The ex-dividend date of this dividend was Friday, February 14th. Bio-Techne’s dividend payout ratio is currently 24.24%.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.